Kura Oncology at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Kura Oncology exhibits at Booth 2229 at ASH 2026 in New Orleans. Kura Oncology supports symposia on acute myeloid leukemia, with a focus on precision treatment and second-opinion review of patient cases. The most specific looks at how menin inhibitors fit into precision care for the disease.
| Organization | ASH 2026 Attendance |
|---|---|
Kura Oncology San Diego, CA | |
Precision oncology company developing ziftomenib, a menin inhibitor for acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements, and other targeted cancer drugs. | Booth Exhibiting at Booth 2229 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00am–10:00am Current Management Paradigms in Acute Myeloid Leukemia – A Second Opinion Case Review Difficult acute myeloid leukemia cases where doctors sought second opinions, paired with reviews of recent data, current management, and ongoing trials. Symposium Fri Dec 11 3:00pm–6:00pm Live Hot Seat™: Advancing Precision Care in Acute Myeloid Leukemia With the Integration of Menin Inhibitors Menin inhibitors for genetically defined acute myeloid leukemia, covering patient selection, combinations, resistance, and differentiation syndrome. |
Find decision makers at Kura Oncology
Tell us what you sell and we’ll find the people at Kura Oncology most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction